Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

34.26 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
3 Cathie Wood Investments That Could Deliver Superior Returns
These three stocks fit Wood's profile for big-time growth. 
Via The Motley Fool
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
Where Will CRISPR Therapeutics Be in 10 Years?
The biotech is part of a revolution in gene-editing therapies. 
Via The Motley Fool
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?
All eyes are on CRISPR Therapeutics' gene editing technology. 
Via The Motley Fool
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
What 17 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
Can This Gene-Editing Stock Deliver 10X Returns?
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
2 Biotech Stocks That Could Help Make You a Fortune
Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent... 
Via Benzinga
Carvana (CVNA) Stock Continues to Move on Improved Outlook
Carvana (CVNA) stock is still a hot topic among traders on Friday after the used-car retailer updated its outlook yesterday. 
Via InvestorPlace
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Wall Street is at max pessimism with this biotech, which might be a big mistake. 
Via The Motley Fool
3 Disruptors I Love Right Now
These stocks could deliver huge returns as the companies transform the economy. 
Via The Motley Fool
TGT Stock Alert: Have Target’s Sales Numbers Peaked?
Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer. 
Via InvestorPlace
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
Wall Street Loves These 3 Growth Stocks -- Should You?
Analysts think all three of these stocks could soar. 
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock
Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock. 
Via InvestorPlace
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
3 Top Healthcare Stocks to Buy for June
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool
Prediction: These 2 Stocks Could Double In the Next Year
It would be a continuation of solid recent performances. 
Via The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
2 Supercharged Stocks to Buy With $100
These stocks are climbing in the double digits. 
Via The Motley Fool
2 Top Trends to Invest $5,000 in Right Now
Renewable energy and gene-editing medical therapies are poised to grow exponentially. 
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
Both stocks are recovering after big losses last year. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.